DrugPatentWatch Database Preview
Details for Patent: 5,753,706
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 5,753,706 protect, and when does it expire?
Patent 5,753,706 protects AURYXIA and is included in one NDA.
This patent has sixteen patent family members in twelve countries.
Summary for Patent: 5,753,706
| Title: | Methods for treating renal failure |
| Abstract: | Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption. |
| Inventor(s): | Hsu; Chen Hsing (Ann Harbor, MI) |
| Assignee: | |
| Application Number: | 08/794,328 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 5,753,706 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Recent additions to Drugs Protected by US Patent 5,753,706
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keryx Biopharms | AURYXIA | ferric citrate | TABLET | 205874 | Sep 5, 2014 | RX | Yes | Start Trial | Y | Start Trial | U-1577 | CONTROL OF SERUM PHOSPHOROUS LEVELS | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 5,753,706
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keryx Biopharms | AURYXIA | ferric citrate | TABLET;ORAL | 205874-001 | Sep 5, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | CONTROL OF SERUM PHOSPHOROUS LEVELS | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,753,706
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 400264 | Start Trial | |||
| Australia | 5441998 | Start Trial | |||
| Australia | 723091 | Start Trial | |||
| Canada | 2272711 | Start Trial | |||
| Germany | 69738824 | Start Trial | |||
| Denmark | 0959878 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
